Mécanismes de l'alloréactivité, des rejets de greffe, p.12 ,
Peut-on séparer GVHD et GVT après greffe de cellules souches médecine/sciences, vol.19, p.540541, 2003. ,
Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies, Tissue Antigens, vol.81, p.183193, 2013. ,
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation, Blood, vol.110, p.45764583, 2007. ,
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria, Blood, vol.117, issue.11, p.32143219, 2011. ,
A biomarker panel for acute graft-versus-host disease, Blood, vol.113, issue.2, p.273278, 2009. ,
The IL-33/ST2 axis augments effector T-cell responses during acute GVHDD, Blood, vol.125, p.31833192, 2015. ,
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death, N. Engl. J. Med, vol.369, p.529539, 2013. ,
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival, JCI Insight, vol.2, p.89798, 2017. ,
Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT, Blood, vol.129, issue.2, p.2017 ,
Biomarker Panel for Chronic Graft-Versus-Host Disease, J. Clin. Oncol. Off. J. Am ,
, Clin. Oncol, vol.34, p.25832590, 2016.
Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.21, p.17391745, 2015. ,
Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.24, p.678686, 2018. ,
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation, Blood, vol.125, issue.1, p.199205, 2015. ,
Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.20, issue.11, p.18611864, 2014. ,
, CRYOSTEM
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia, N. Engl. J. Med, vol.314, p.729735, 1986. ,
Major Histocompatibility Complex and Hematopoietic Stem Cell Transplantation: Beyond the Classical HLA Polymorphism, Int. J. Mol. Sci, vol.19, issue.2, 2018. ,
Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.15, p.856863, 2009. ,
Minor histocompatibility antigens in human stem cell transplantation, Exp. Hematol, vol.31, p.743 ,
A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study, Lancet Haematol, vol.2, issue.1, pp.21-29, 2015. ,
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The, Biomarker Working Group Report, vol.21, p.780, 2014. ,
Discovery and validation of graft-versus-host disease biomarkers, Blood, vol.121, p.585594, 2013. ,
Biomarkers for posttransplantation outcomes, Blood, vol.131, p.2193 ,
High HLA-DP Expression and Graft-versus-Host Disease, N. Engl. J. Med, vol.373, p.599609, 2015. ,
The IL-33/ST2 pathway: therapeutic target and novel biomarker, Nat. Rev. Drug Discov, vol.7, p.827840, 2008. ,
ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease, Sci. Transl. Med, vol.7, pp.308-160, 2015. ,
Modern approaches to HLA-haploidentical blood or marrow transplantation, Nat. Rev. Clin. Oncol, vol.13, issue.1, p.1024, 2016. ,
Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients, Ann. Hematol, 2018. ,
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?, Blood Adv, vol.2, issue.11, p.11801186, 2018. ,
, Comparable Outcomes for Hematologic Malignancies after HLA
, Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation, Adv. Hematol, vol.2015, p.431923, 2015.
Plasma-derived proteomic biomarkers in human leukocyte antigenhaploidentical or human leukocyte antigen-matched bone marrow transplantation using posttransplantation cyclophosphamide, Haematologica, vol.102, issue.5, p.932940, 2017. ,
L'immunothérapie au service de la chimiothérapie, de nouvelles avancées, MS Médecine Sci. ISSN, vol.32, pp.353-361, 2016. ,
Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.16, p.907914, 2010. ,
Specifically differentiated T cell subset promotes tumor immunity over fatal immunity, J. Exp. Med, vol.214, p.35773596, 2017. ,
Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation, Hematol. Oncol. Stem Cell Ther, vol.10, p.233238, 2017. ,
The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters, Blood Rev, vol.31, p.173183, 2017. ,
The Dynamic Role of the IL-33/ST2 Axis in Chronic Viralinfections: Alarming and Adjuvanting the Immune Response, vol.9, p.3744, 2016. ,
IL-33 receptor ST2 amplifies the expansion of NK cells and enhances host defense during mouse cytomegalovirus infection, J. Immunol. Baltim. Md, vol.194, p.59485952, 1950. ,
The IL-33/ST2 axis: Role in health and disease, Cytokine Growth Factor Rev, vol.26, p.615623, 2015. ,
From proteomics to discovery of first-in-class ST2 inhibitors active in vivo, JCI Insight, vol.3, p.14, 2018. ,
, Les lymphocytes T dans la GVHD